PrimeRFP SCOUT · Federal Contract Recompete Brief

19AQMM19F24042019-2020 fluarix and flulaval vaccine delivery — Glaxosmithkline LLC

Glaxosmithkline LLC holds $3.0B across 194 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent V797P2298D. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Aug 20, 2019 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Acquisitions - Aqm Momentum

Awarding office

Glaxosmithkline LLC

Recipient

Aug 20, 2019

PoP end

$-16,875

Obligated

$606K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Glaxosmithkline LLC — $90

Contract facts

Federal

Contract number19AQMM19F2404

Also listed as19AQMM-19-F-2404

Also listed asV797P2298D-19AQMM19F2404

AgencyAcquisitions - Aqm Momentum

Awarding officeAcquisitions - Aqm Momentum

Awarding agencyDepartment of State (DOS)

Funding agencyDepartment of State (DOS)

IncumbentGlaxosmithkline LLC

CAGE667E9

UEIFRHTPHMZMX47

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDVV797P2298D

Place of performanceSTERLING VA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startJul 31, 2019

PoP end (current)Aug 20, 2019

Obligated$-16,875

Current value$606K

Potential value$606K

2019-2020 FLUARIX AND FLULAVAL VACCINE DELIVERY ORDER. RESERVATIONS 1003465297, AND 1003454345. is a federal award for Acquisitions - Aqm Momentum held by Glaxosmithkline LLC. Estimated value $606K ($-16,875 obligated). Current period of performance ends Aug 20, 2019. Last award drew 1 bidder. Place of performance: STERLING VA.

2019-2020 FLUARIX AND FLULAVAL VACCINE DELIVERY ORDER. RESERVATIONS 1003465297, AND 1003454345.

Recompete timing

Public

● Past PoP end (2558 days ago)

Current PoP ended Aug 20, 2019 (2558 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Glaxosmithkline LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($3.0B) · all agencies

Department of Health and Human Services (HHS)$3.0B · 100%Department of Defense (DOD)$1.7M · 0%Department of Veterans Affairs (VA)$1.5M · 0%Department of State (DOS)$1.2M · 0%

Open full company profile →

Related awards

Same parent · incumbent

75A50125F61019

FILL/FINISH DOD AS03 ADJUVANT CLIN 1006E

$491K

Aug 30, 2026

75A50126F61020

TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIOR…

$493K

Oct 29, 2026

15F06724F0001366

GSK TRAVEL VACCINES

$115K

Dec 31, 2026

15F06726F0000234

GSK VACCINES TERMS AND CONDITIONS REMAIN THE SAME - BPA 15F06722A0000187

$105K

Dec 31, 2026

75A50124F61014

THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL …

$18.4M

Feb 21, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 19AQMM19F2404?

19AQMM19F2404 (2019-2020 fluarix and flulaval vaccine delivery) is a Acquisitions - Aqm Momentum award with a potential value of $606K, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 19AQMM-19-F-2404?

19AQMM-19-F-2404 is the dashed form of PIID 19AQMM19F2404 (2019-2020 fluarix and flulaval vaccine delivery), held by Glaxosmithkline LLC. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 19AQMM19F2404?

Acquisitions - Aqm Momentum awarded 19AQMM19F2404 to Glaxosmithkline LLC (potential $606K).

Who is the incumbent on 19AQMM19F2404?

Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Aug 20, 2019.

When does Glaxosmithkline LLC’s 19AQMM19F2404 come up for recompete?

SCOUT tracks a period-of-performance end of Aug 20, 2019. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Sep 30, 2021